ContributorsPublishersAdvertisers

Nivolumab/Encorafenib/Cetuximab Triplet Elicits High Response Rate in MSS, BRAF V600E-Mutant mCRC

onclive.com
 2022-01-22

The addition of nivolumab to encorafenib and cetuximab elicited a high response rate and an acceptable safety profile in patients with refractory microsatellite stable, BRAF V600E–mutant metastatic colorectal cancer, according to findings from a phase 1/2 trial. The addition of nivolumab (Opdivo) to encorafenib (Braftovi) and cetuximab (Erbitux)...

www.onclive.com

Comments / 0

Comments / 0